Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Will Use siRNA Tools, GeneBlocs Tech to Help Sankyo Validate Drug Targets

NEW YORK, May 17 (GenomeWeb News) - Atugen will use its siRNA technology and GeneBlocs platform to help Japanese drug maker Sankyo validate certain undisclosed therapeutic targets.


Atugen, based in Berlin, will use its tools, which also include delivery reagents and functional assays, to validate an undisclosed number of Sankyo targets.

This is the second collaboration between the two companies.

Financial details of the agreement were not disclosed.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.